Primary and secondary hemophagocytic lymphohistiocytosis: Clinical features, pathogenesis and therapy

Expert Review of Clinical Immunology

Volumn 6, Issue 1, 2010, Pages 137-154

  Gupta, Sumit ^a   Weitzman, Sheila ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Hemophagocytosis; Histiocytosis; HLH; Immune deficiency; Review; Therapy

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; CYCLOSPORIN A; ETOPOSIDE; GRANZYME; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; APOPTOSIS; CD8+ T LYMPHOCYTE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EPSTEIN BARR VIRUS; EXOCYTOSIS; FAMILIAL DISEASE; FEVER; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HEPATOSPLENOMEGALY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LABORATORY DIAGNOSIS; MACROPHAGE ACTIVATION SYNDROME; OPPORTUNISTIC INFECTION; PATHOGENESIS; PATHOPHYSIOLOGY; PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; REVIEW; SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; TARGET CELL;

APOPTOSIS; CYTOTOXICITY, IMMUNOLOGIC; EPSTEIN-BARR VIRUS INFECTIONS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, NATURAL; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; PREDICTIVE VALUE OF TESTS; RISK FACTORS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 77649169379     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.58     Document Type: Review

References (188)

1. Henter JI, Elinder G, Soder O, Ost A. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr. Scand. 80, 428-435 (1991).
2. Farquhar JW, Claireaux AE. Familial haemophagocytic reticulosis. Arch. Dis. Child. 27, 519-525 (1952).
3. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 124(4), 783-801 (2006).
4. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 22(11), 633-640 (2001).
5. Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G. Relationship between CD107a expression and cytotoxic activity. Cell Immunol. 254(2), 149-154 (2009).
6. Strowig T, Brilot F, Munz C. Noncytotoxic functions of NK cells: Direct pathogen restriction and assistance to adaptive immunity. J. Immunol. 180(12), 7785-7791 (2008).
7. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17, 189-220 (1999).
8. Dalbeth N, Gundle R, Davies RJ et al. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a recipricol program of activation. J. Immunol. 173(10), 6418-6426 (2004).
9. Medzhitov R. Recognition of microorganisms and activation of the immune respose. Nature 449(7164), 819-826 (2007).
10. Badovinac VP, Harty JT. CD8+ T-cell homeostasis after infection: Setting the 'curve'. Microbes Infect. 4, 441-447 (2002).
11. de Saint Basile G, Fischer A. Defective cytotoxic granule-mediated cell death pathway impairs T lymphocyte homeostasis. Curr. Opin. Rheumatol. 15, 436-445 (2003).
12. Verbsky JW, Grossman WJ. Hemophagocytic lymphohistiocytosis: Diagnosis, pathophysiology, treatment, and future perspectives. Ann. Med. 38, 20-31 (2006).
13. Hersperger AR, Makedonas G, Betts MR. Flow cytometric detection of perforin upregulation in human CD8 T cells. Cytometry A 73(11), 1050-1057 (2008).
14. Stinchcombe JC, Griffiths GM. Secretory mechanisms in cell-mediated cytotoxicity. Annu. Rev. Cell. Dev. Biol. 23, 495-517 (2007).
15. Neeft M, Weiffer M, De Jong AS et al. Munc13-4 is an effector of rab27a and controls secretion of lysosomes in hematopoietic cells. Mol. Biol. Cell 16(2), 731-741 (2005).
16. Fukuda M. Regulation of secretory vesicle traffic by Rab small GTPases. Cell. Mol. Life Sci. 65(18), 2801-2813 (2008).
17. Betts MR, Brenchley JM, Price DA et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281(1-2), 65-78 (2003).
18. Filipovich AH. Hemophagocytic lymphohistiocytosis and related disorders. Curr. Opin. Allergy Clin. Immunol. 6, 410-415 (2006).
19. Grossman WJ, Verbsky JW, Tollefsen BL et al. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 104(9), 2842-2848 (2004).
20. Pipkin ME, Lieberman J. Delivering the kiss of death: progress on understanding how perforin works. Curr. Opin. Immunol. 19(3), 301-308 (2007).
21. Liu C, Walsh CM, Young JD. Perforin: Structure and function. Immunol. Today 16, 194-201 (1995).
22. Urrea Moreo R, Gil J, Rodriguez-Sainz C et al. Functional assessment of perforin C2 domain mutations illustrates the critical role for calcium-dependent binding in perforin cytotoxic function. Blood 113(2), 338-346 (2009).
23. Pinkoski MJ, Green DR. Lymphocyte apoptosis: Refining the paths to perdition. Curr. Opin. Hematol. 9, 43-49 (2002).
24. Metkar SS, Wang B, Aguilar-Santelises M et al. Cytotoxic cell granule-mediated apoptosis: perforin delivers granzyme B-serglycin complexes into target cells without plasma membrane pore formation. Immunity 16, 417-428 (2002).
25. Voskoboinik I, Smyth MJ, Trapani JA. Perforin-mediated target-cell death and immune homeostasis. Nat. Rev. Immunol. 6, 940-952 (2006).
26. Palm-Apergi C, Lorents A, Padari K, Pooga M, Hallbrink M. The membrane repair response masks membrane disturbances caused by cell-penetrating peptide uptake. FASEB J. 23(1), 214-223 (2009).
27. Keefe K, Shi L, Feske S et al. Perforin triggers a plasma membrane-repair response that facilitates CTL induction of apoptosis. Immunity 23(3), 249-262 (2005).
28. Bots M, Medema JP. Granzymes at a glance. J. Cell Sci. 119, 5011-5014 (2006).
29. Fellows E, Gil-Parrado S, Jenne DE, Kurschus FC. Natural killer cell-derived human granzyme H induces an alternative, caspase-independent cell-death program. Blood 110(2), 544-552 (2007).
30. Bratke K, Kuepper M, Bade B, Virchow JC, Luttmann W. Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood. Eur. J. Immunol. 35(9), 2608-2616 (2005).
31. Snoeck HW, Van Bockstaele DR, Nys G et al. Interferon g selectively inhibits very primitive CD342+CD38- and not more mature CD34+CD38+ human hematopoietic progenitor cells. J. Exp. Med. 180(3), 1177-1182 (1994).
32. Zeerleder S, Hack CE, Caliezi C et al. Activated cytotoxic T cells and NK cells in severe sepsis and septic shock and their role in multiple organ dysfunction. Clin. Immunol. 116(2), 158-165 (2005).
33. Sato T, Seller C, Young NS, Maciejeskwi JP. Hematopoietic inhibition by interferon-g is partially mediated through interferon regulatory factor-1. Blood 86(9), 3373-3380 (1995).
34. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon g are essential for the disorder. Blood 104, 735-743 (2004).
35. Osugi Y, Hara J, Tagawa S et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood 89(11), 4100-4103 (1997).
36. Marcenaro S, Gallo F, Martini S et al. Analysis of natural killer-cell function in familial hemphagocytic lymphohistiocytosis (FHL): Defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease. Blood 108, 2316-2323 (2006).
37. Billiau AD, Roskams T, Van Damme-Lombaerts R, Matthys P, Wouters C. Macrophage activation syndrome: Characteristic findings on livery biopsy illustrating the key role of activated, IFN-g-producing lymphocytes and IL-6- and TNF-a-producing macrophages. Blood 105(4), 1648-1651 (2005).
38. Haddad E, Sulis ML, Jabado N et al. Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis. Blood 89(3), 794-800 (1997).
39. Imashuku S, Hibi S, Sako M et al. Heterogeneity of immune markers in hemophagocytic lymphohistiocytosis: Comparitive study of 9 familial and 14 familial inheritance-unproven cases. J. Pediatr. Hematol. Oncol. 20(3), 207-214 (1998).
40. Schneider EM, Lorenz I, Muller-Rosenberger M et al. Hemophagocytic lymphohistiocytosis is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer-cell-induced apoptosis. Blood 89, 4100-4103 (2002).
41. Imashuku S, Ikushima S, Esumi N, Todo S, Saito M. Serum levels of interferon-g, cytotoxic factor and soluble interleukin-2 receptor in childhood hemophagocytic syndromes. Leuk. Lymphoma 3, 287 (1991).
42. Henter JI, Elinder G, Soder O et al. Hypercytokinemia in familial hemophagocytosis. Blood 78, 2918-2922 (1991).
43. Fujiwara F, Hibi S, Imashuku S. Hypercytokinemia in hemophagocytic syndrome. Am. J. Pedatr. Hematol. Oncol. 15, 92-98 (1993).
44. Ohga S, Matsuzaki A, Nishizaki M et al. Inflammatory cytokines in virus-associated hemophagocytic syndrome: interferon-g as a sensitive indicator of disease activity. Am. J. Pedatr. Hematol. Oncol. 15, 291-298 (1993).
45. Akashi K, Hayashi S, Gondo H et al. Involvement of interferon-g and macrophage colony-stimulating factor in pathogenesis of hemophagocytic lymphohistiocytosis in adults. Br. J. Haematol. 87, 243-250 (1994).
46. Tamura K, Kanazawa T, Tsukada S et al. Increased serum monocyte chemoattractant protein-1, macrophage inflammatory protein-1b, and interleukin-8 concentrations in hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 51(5), 662-668 (2008).
47. Van Dommelen SLH, Sumaria N, Schreiber RD et al. Perforin and granzyme have distinct roles in defensive immunity and immunopathology. Immunity 25, 835-848 (2006).
48. Sullivan KE, Delaat CA, Douglas SD, Filipovich AH. Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first-degree relatives. Pediatr. Res. 44, 465-468 (1998).
49. Schneider EM, Lorenz I, Walther P, Janka GE. Natural killer deficiency: A minor or major factor in the manifestation of hemophagocytic lymphohistiocytosis? J. Pediatr. Hematol. Oncol. 25(9), 680-683 (2003).
50. Larroche C, Mouthon L. Pathogenesis of hemophagocytic syndrome (HPS). Autoimmun. Rev. 3, 69-75 (2004).
51. Badovinac VP, Porter BB, Harty JT. Programmed contraction of CD8+ T cells after infection. Nat. Immunol. 3(7), 619-626 (2002).
52. Badovinac VP, Porter BB, Harty JT. CD8+ T cell contraction is controlled by early inflammation. Nat. Immunol. 5(8), 809-817 (2004).
53. Andrews DM, Andoniou CD, Fleming P, Smyth MJ, Degli-Esposti MA. The early kinetics of cytomegalovirus-specific CD8+ T-cell responses are not affected by antigen load or the absence of perforin or g interferon. J. Virol. 82, 4931-4937 (2008).
54. Kagi D, Odermatt B, Mak TW. Homeostatic regulation of CD8+ T cells by perforin. Eur. J. Immunol. 29, 3262-3272 (1999).
55. Ohadi M, Lalloz MRA, Sham P et al. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping. Am. J. Hum. Genet. 64, 165-171 (1999).
56. Stepp SE, Dufourcq-Lagelouse R, Le Deist F et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 286, 1957-1959 (1999).
57. Kogawa K, Lee SM, Villanueva J et al. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood 99(1), 61-66 (2002).
58. Ueda I, Morimoto A, Inaba T et al. Characteristic perforin gene mutations of haemophagocytic lymphohistiocytosis patients in Japan. Br. J. Haematol. 121, 503-510 (2003).
59. Molleran Lee S, Villanueva J, Sumegi J et al. Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in North American families with haemophagocytic lymphohistiocytosis. J. Med. Genet. 41(2), 137-144 (2004).
60. Lieberman J. The ABCs of granulemediated cytotoxicity: new weapons in the arsenal. Nat. Rev. Immunol. 3, 361-370 (2003).
61. Molleran Lee S, Sumegi J, Villanueva J et al. Patients of African ancestry with hemophagocytic lymphohistiocytosis share a common haplotype of PRF1 with a 50DELT mutation. J. Pediatr. 149, 134-137 (2006).
62. Clementi R, Zur Stadt U, Savoldi G et al. Six novel mutations in the PRF1 gene in children with haemophagocytic lymphohistiocytosis. J. Med. Genet. 38, 643-646 (2001).
63. Trizzino A, Zur Stadt U, Risma K et al. Genotype phenotype study of familial haemophagocytic lymphohistiocytosis due to perforin mutations. J. Med. Genet. 45, 15-21 (2008).
64. Voskoboinik I, Sutton VR, Ciccone A et al. Perforin activity and immune homeostasis: The common A91V polymorphisim in perforin results in both presynaptic and postsynaptic defects in function. Blood 110(4), 1184-1190 (2007).
65. Zhang K, Johnson JA, Biroschak J et al. Familial haemophagocytic lymphohistiocytosis in patients who are heterozygous for the A91V perforin variation is often associated with other genetic defects. Int. J. Immunogenet. 34(4), 231-233 (2007).
66. Dufourcq-Lagelouse R, Jabado N, Le Deist F et al. Linkage of familial hemophagocytic lymphhistiocytosis to 10q21-22 and evidence for heterogeneity. Am. J. Hum. Genet. 64, 172-179 (1999).
67. Graham GE, Graham LM, Bridge PJ et al. Further evidence for genetic heterogeneity in familial hemophagocytic lymphohistiocytosis (FHLH). Pediatr. Res. 48(2), 227-232 (2000).
68. Feldmann J, Callebaut I, Raposo G et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 115, 461-473 (2003).
69. Pivot-Pajot C, Varoqueaux F, De Saint Basile G, Bourgain SG. Munc13-4 regulates granule secretion in human neutrophils. J. Immunol. 180(10), 6786-6797 (2008).
70. Menasche G, Pastural E, Feldmann J et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat. Genet. 25(2), 173-176 (2000).
71. Ishii E, Ohga S, Imashuku S et al. Review of hemophagocytic lymphohistiocytosis (HLH) in children with focus on Japanese experiences. Crit. Rev. Oncol. Hematol. 53, 209-223 (2005).
72. Santoro A, Cannella S, Trizzino A et al. Mutations affecting mRNA splicing are the most common molecular defect in patients with familial hemophagocytic lymphohistiocytosis type 3. Haematologica 93, 1086-1090 (2008).
73. Rudd E, Bryceson YT, Zheng C et al. Spectrum, and clinical and functional implications of UNC13D mutations in familial haemophagocytic lymphohistiocytosis. J. Med. Genet. 45(3), 134-141 (2008).
74. Ueda I, Ishii E, Morimoto A et al. Correlation between phenotypic heterogeneity and gene mutational characteristics in familial hemophagocytic lymphohistiocytosis (FHL). Pedatr. Blood Cancer 46, 482-488 (2006).
75. Zur Stadt U, Beutel K, Kolberg S et al. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11 and RAB27A. Hum. Mutat. 27(1), 62-68 (2006).
76. Bryceson YT, Rudd E, Zheng C et al. Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagoctic lymphohistiocytosis 4 (FHL4) patients. Blood 110(6), 1906-1915 (2007).
77. Crozat K, Hoebe K, Ugolini S et al. Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: A mouse model of type 3 familial hemophagocytic lymphohistiocytosis. J. Exp. Med. 204(4), 853-863 (2007).
78. Zur Stadt U, Schmidt S, Kasper B et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum. Mol. Gen. 14(6), 827-834 (2005).
79. Janka G, zur Stadt U. Familial and acquired hemophagocytic lymphohistiocytosis. Hematology Am. Soc. Hematol. Educ. Program 82-88 (2005).
80. Yamamoto K, Ishii E, Horiuchi H et al. Mutations of syntaxin 11 and SNAP23 genes as causes of familial hemophagocytic lymphohistiocytosis were not found in Japanese people. J. Hum. Genet. 50, 600-603 (2005).
81. Arenson LN, Brickshawana A, Segovis CM et al. Cutting edge: Syntaxin 11 regulates lymphocyte-mediated secretion and cytotoxicity. J. Immunol. 179(6), 3397-3401 (2007).
82. Kaplan J, De Domenico I, McVey Ward D. Chediak-Higashi syndrome. Curr. Opin. Hematol. 15, 22-29 (2008).
83. Enders A, Zieger B, Schwarz K et al. Lethal hemphagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood 108, 81-87 (2006).
84. Engel P, Eck MJ, Terhorst C. The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat. Rev. Immunol. 3, 813-821 (2003).
85. Grunebaum E, Zhang J, Dadi H, Roifman CM. Haemophagocytic lymphohistiocytosis in X-linked severe combined immunodeficiency. Br. J. Haematol. 108, 834-837 (2000).
86. Schultz KAP, Neglia JP, Smith AR et al. Familial hemophagocytic lymphohistiocytosis in two brothers with X-linked agammaglobulinemia. Pediatr. Blood Cancer 51, 293-295 (2008).
87. Stinchcombe J, Bossi G, Griffiths G. Linking albinism and immunity: The secrets of secretory lysosomes. Science 305(5680), 55-59 (2004).
88. Schmid JP, Ho C, Diana J et al. A Griscelli syndrome type 2 murine model of hemophagocytic lymphohistiocytosis (HLH). Eur. J. Immunol. 38, 3219-3225 (2008).
89. Stinchcombe J, Bossi G, Booth S, Griffiths GM. The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity 15(5), 751-761 (2001).
90. Nagle DL, Karim MA, Woolf EA et al. Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. Nat. Genet. 14(3), 307-311 (1996).
91. Fontana S, Parolini S, Vermi W et al. Innate immunity defects in Hermansky- Pudlak type 2 syndrome. Blood 107(12), 4857-4864 (2006).
92. Ma CS, Nichols KE, Tangye SG. Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules. Annu. Rev. Immunol. 25, 337-379 (2007).
93. Tabata Y, Villanueva J, Lee SM et al. Rapid detection of intracellular SH2D1A protein in cytotoxic lymphocytes from patients with X-linked lymphoproliferative disease and their family members. Blood 105(8), 3066-3071 (2005).
94. Rigaud S, Fondaneche MC, Lambert N et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 444(7115), 110-114 (2006).
95. Janka GE. Familial erythrophagocytic lymphohistiocytosis. Eur. J. Pediatr. 140, 221-230 (1983).
96. Arico M, Janka G, Fischer A et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. Leukemia 10, 197-203 (1996).
97. Hirst WJ, Layton DM, Singh S, Mieli-Vergani G, Chessells JM. Haemophagocytic lymphohistiocytosis: experience at two U.K. centres. Br. J. Haematol. 88, 731-739 (1994).
98. Morrell DS, Pepping MA, Scott P, Esterly NB, Drolet BA. Cutaneous manifestations of hemophagocytic lymphohistiocytosis. Arch. Dermatol. 138, 1208-1212 (2002).
99. Horne A, Trottestam H, Arico M et al. Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis. Br. J. Haematol. 140, 327-335 (2007).
100. Stapp J, Wilkerson S, Stewart D et al. Fulminant neonatal liver failure in siblings: probably congenital hemophagocytic lymphohistiocytosis. Pediatr. Dev. Pathol. 9(3), 239-244 (2006).
101. Henter JI, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. Semin. Oncol. 28, 342-347 (1991).
102. Gupta A, Tyrrell P, Valani R et al. The role of the initial bone marrow aspirate in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 51, 402-404 (2008).
103. Goo HW, Weon YC. A spectrum of neuroradiological findings in children with haemophagocytic lymphohistiocytosis. Pediatr. Radiol. 37, 1110-1117 (2007).
104. Kataoka Y, Todo S, Morioka Y et al. Impaired natural killer activity and expression of interleukin-2 receptor antigen in familial erythrophagocytic lymphohistiocytosis. Cancer 65, 1937-1941 (1990).
105. Perez N, Virelizier J, Arenzana-Seisdedos F, Fischer A, Griscelli C. Impaired natural killer cell activity in lymphohistiocytosis syndrome. J. Pediatr. Hematol. Oncol. 104, 569-573 (1984).
106. Eife R, Janke GE, Belohrasky BH. Natural killer cell function and interferon production in familial hemophagocytic lymphohistiocytosis. Pediatr. Hematol. Oncol. 6, 265-272 (1989).
107. Arico M, Danesino C, Pende D, Moretta L. Pathogenesis of hemophagocytic lymphohistiocytosis. Br. J. Haematol. 114, 761-769 (1991).
108. Filipovich A. Hemophagocytic lymphohistiocytosis. Immunol. Allergy Clin. N. Am. 22, 281-300 (2002).
109. Janka G, Muller-Rosenberger M, Schneider EM. Persistent defect of cellular cytotoxicity after Epstein-Barr virusassociated hemophagocytic lymphohistiocytosis. Blood 96, 36b (2001).
110. Janka G, Schneider EM. Modern management of children with haemophagocytic lymphohistiocytosis. Br. J. Haematol. 124, 4-14 (2004).
111. Henter JI, Horne A, Arico M et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 48, 124-131 (2007).
112. Palazzi DL, McClain KL, Kaplan SL. Hemophagocytic syndrome in children: An important diagnostic consideration in fever of unknown origin. Clin. Infect. Dis. 36, 306-312 (2003).
113. Castillo L. High elevated ferritin levels and the diagnosis of HLH/Sepsis/SIRS/ MODS/MAS. Pediatr. Blood Cancer 51, 710-711 (2008).
114. Suster S, Hilsenbeck S, Rywlin AM. Reactive histiocytic hyperplasia with hemophagocytosis in hematopoietic organs: A reevaluation of the benign hemophagocytic proliferations. Hum. Pathol. 19, 705-712 (1988).
115. Strauss R, Neureiter D, Westenburger B et al. Multifactorial risk analysis of bone marrow histiocytic hyperplasia with hemophagocytosis in critically ill medical patients - a postmortem clinicopathologic analysis. Crit. Care Med. 32(6), 1316-1321 (2004).
116. Gauvin F, Toledano B, Champagne J, Lacroix J. Reactive hemophagocytic syndrome presenting as a component of multiple organ dysfunction syndrome. Crit. Care Med. 28(9), 3341-3345 (2000).
117. Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 50, 1227-1235 (2008).
118. Kapoor S. Distinguishing hemophagocytic lymphohistiocytosis from hemochromatosis in patients with hyperferritinemia. Pediatr. Blood Cancer 50, 1287-1297 (2008).
119. Allen CE, McClain KL, Filipovich L. Highly elevated ferritin levels and the diagnosis of HLH/sepsis/SIRS/MODS/ MAS - response. Pediatr. Blood Cancer 51, 711 (2008).
120. Emminger W, Zlabinger GJ, Fritsch G, Urbanek R. CD14dim/CD16bright monocytes in hemophagocytic lymphohistiocytosis. Eur. J. Immunol. 31, 1716-1719 (2001).
121. Schaer DJ, Schleiffenbaum B, Kurrer M et al. Soluble hemoglobin- haptoglobin scavenger receptor CD163 as a lineagespecific marker in the reactive hemophagocytic syndrome. Eur. J. Hematol. 74, 6-10 (2005).
122. Moller HJ, Moestrup SK, Weis N et al. Macrophage serum markers in pneumococcal bacteremia: prediction of survival by soluble CD163. Crit. Care Med. 34(10), 2561-2566 (2006).
123. Bleesing J, Prada A, Siegel DM et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor a-chain in macrophage activation syndrome and unrelated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 56(3), 965-971 (2007).
124. Moller HJ, Gronbaek H, Schiodt FV et al. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J. Hepatol. 47(5), 671-676 (2007).
125. Ishii E, Ohga S, Imashuku S et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int. J. Hematol. 86, 58-65 (2007).
126. Allen M, De Fusco C, Legrand F et al. Familial hemophagocytic lymphohistiocytosis: how late can the onset be? Haematologica 86, 499-503 (2001).
127. Nagafuji K, Nonami A, Kumano T et al. Perforin gene mutations in adult-onset hemophagocytic lymphohistiocytosis. Haematologica 92, 978-981 (2007).
128. Jordan MB, Filipovich AH. Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: A journey of a thousand miles begins with a single (big) step. BMT 42, 433-437 (2008).
129. Risdall RJ, McKenna RW, Nesbit ME et al. Virus-associated hemophagocytic syndrome: A benign histiocytic proliferation distinct from malignant histiocytosis. Cancer 44(3), 993-1002 (1979).
130. Rouphael NG, Talati NJ, Vaughan C et al. Infections associated with haemophagocytic syndrome. Lancet Infect. Dis. 7, 814-822 (2007).
131. Henter JI, Chow CB, Leung CW, Lau YL. Cytotoxic therapy for severe avian influenza A (H5N1) infection. Lancet 367(9513), 870-873 (2006)
132. Kasahara Y, Yachie A. Cell type specific infection of Epstein-Barr virus (EBV) in EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Crit. Rev. Oncol. Hematol. 44, 283-294 (2002).
133. Kasahara Y, Yachie A, Takei K et al. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood 98, 1882-1888 (2001).
134. Imashuku S. Systemic type Epstein-Barr virus-related lymphoproliferative diseases in children and young adults: Challenges for pediatric hemato-oncologists and infectious disease specialists. Pediatr. Hematol. Oncol. 24, 563-568 (2007).
135. Chuang HC, Lay JD, Hsieh WC et al. Epstein-Barr virus LMP1 inhibits the expression of SAP gene and upregulates Th1 cytokines in the pathogenesis of hemophagocytic syndrome. Blood 106(9), 3090-3096 (2005).
136. Wada T, Kurokawa T, Toma T et al. Immunophenotypic analysis of Epstein- Barr virus (EBV)-infected CD8+ T cells in a patient with EBV-associated hemophagocytic lymphohistiocytosis. Eur. J. Hematol. 79, 72-75 (2007).
137. Beutel K, Janka GE, Schneider ME. EBV-associated hemophagocytic lymphohistiocytosis (HLH) in German children. Med. Pediatr. Oncol. 38, 224 (2002).
138. Janka G, Imashuku S, Elinder G, Schneider M, Henter JI. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol. Oncol. Clin. North Am. 12, 435-444 (1998).
139. O'Brien MM, Lee-Kim Y, George YI et al. Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 50(2), 381-383 (2008).
140. Kuzmanovic M, Rasovic N, Micic D et al. Epstein-Barr virus associated hemophagocytic lymphohistiocytosis during maintenance treatment of acute lymphoblastic leukemia. Pediatr. Blood Cancer 46(7), 832 (2006).
141. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: A potentially fatal complication of rheumatic disorders. Arch. Dis. Child. 85(5), 421-426 (2001).
142. Avcin T, Tse SM, Schneider R, Ngan B, Silverman ED. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J. Pediatr. 148(5), 683-686 (2006).
143. Ramanan AV, Schneider R. Macrophage activating syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 30, 401-403 (2003).
144. Stephan JL, Kone-Paut I, Galambrun C et al. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology 40, 1285-1292 (2001).
145. Grom AA. Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: The same entities? Curr. Opin. Rheumatol. 15, 587-590 (2003).
146. Ramanan AV, Schneider R. Macrophage activation syndrome - what's in a name! J. Rheumatol. 30(12), 2513-2516 (2003).
147. Grom AA, Villanueva J, Lee S et al. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J. Pediatr. 142, 292-296 (2003).
148. Villanueva J, Lee S, Giannini EH et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis. Res. Ther. 7, R30-R37 (2005).
149. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J. Rheumatol. 34(5), 1133-1138 (2007).
150. Behrens EM. Macrophage activation syndrome in rheumatic disease: what is the role of the antigen presenting cell? Autoimmun. Rev. 7, 305-308 (2008).
151. Ramanan AV, Grom AA. Does systemiconset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis? Rheumatology 44, 1350-1353 (2005).
152. Donn R, Ellison S, Lamb R et al. Genetic loci contributing to hemophagocytic lymphohistiocytosis do not confer susceptibility to systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58(3), 869-874 (2008).
153. Hazen MM, Woodward AL, Hofmann I et al. Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum. 58(2), 567-570 (2008).
154. Ravelli A, Magni-Manzoni S, Pistorio A et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J. Pediatr. 146, 598-604 (2005).
155. Kelly A, Ramanan AV. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr. Opin. Rheumatol. 19, 477-481 (2007).
156. Henter JI. Biology and treatment of familial hemophagocytic lymphohistiocytosis: importance of perforin in lymphocyte-mediated cytotoxicity and triggering of apoptosis. Med. Pediatr. Oncol. 38, 305-309 (2002).
157. Ambruso DR, Hays T, Zwartjes WJ, Tubergen DG, Favara BE. Successful treatment of lymphohistiocytic reticulosis with phagocytosis with epipodophyllotoxin VP 16-213. Cancer 45, 2516-2520 (1980).
158. Fischer A, Virelizier J, Arenzana-Seisdedos F et al. Treatment of four patients with erythrophagocytic lymphohistiocytosis by a combination of epipodophphyllotoxin, steroids, intrathecal methotrexate and cranial irradiation. Pediatrics 76, 263-268 (1985).
159. Stephan JL, Donadieu J, Le Deist F et al. Treatment of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins, steroids and cyclosporin A. Blood 82, 2319-2323 (1993).
160. Fischer A, Cerf-Bensussan N, Blanche S et al. Allogeneic bone marrow transplantation for erythrophagocytic lymphohistiocytosis. J. Pediatr. 108(2), 267-270 (1986). (Pubitemid 16124823)
161. Caselli D, Aricò M; EBMT Paediatric Working Party. The role of BMT in childhood histiocytoses. Bone Marrow Transplant 41, S8-S13 (2008).
162. Henter JI, Samuelsson-Horne A, Arico M et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 100, 2367-2373 (2002).
163. Filipovich AH, Imashuku S, Henter JI, Sullivan KE. Healing hemophagocytosis. Clin. Immunol. 117, 121-124 (2005).
164. Imashuku S, Kuriyama K, Sakai R et al. Treatment of Epstein-Barr virus-associated hemophagocytosis (EBV-HLH) in young adults: A report from the HLH study center. Med. Pediatr. Oncol. 41(2), 103-109 (2003).
165. Mahlaoui N, Ouachee-Chardin M, de Saint Basile G et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymoctye globulins: A single-center retrospective report of 38 patients. Pediatrics 120(3), e622-e628 (2007).
166. Imashuku S. Etoposide-related secondary acute myeloid leukemia (t-AML) in hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 48, 121-123 (2007).
167. Imashuku S, Kuriyama K, Teramura T et al. Requirement for etoposide in the treatment of Epstein-Barr virusassociated hemophagocytic lymphohistiocytosis. J. Clin. Oncol. 19(10), 2665-2673 (2001).
168. Trottestam H, Beutel K, Meeths M et al. Treatment of then X-linked lymphoproliferative, Griscelli and Chediak-Higashi syndromes by HLH directed therapy. Pediatr. Blood Cancer 52(2), 268-272 (2009).
169. Imashuku S, Teramura T, Tauchi H et al. Longitudinal follow-up of patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Haematologica 89, 183-188 (2004).
170. Baker KS, Filipovich AH, Gross TG et al. Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. BMT 42, 175-180 (2008).
171. Ouachee-Chardin M, Elie C, De Saint Basile G et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: A single-center report of 48 patients. Pediatrics 117(4), e743-e750 (2006).
172. Satwani P, Cooper N, Rao K, Veys P, Amrolia P. Reduced intensity conditioning and allogeneic stem cell tranplantation in childhood malignant and nonmalignant disease. BMT 41(2), 173-182 (2008). (Pubitemid 351188915)
173. Cooper N, Rao K, Gilmour K et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood 107(3), 1233-1236 (2006).
174. Chen R, Lin K, Lin D et al. Immunomodulation treatment for childhood virus-associated haemophagocytic lymphohistiocytosis. Br. J. Haematol. 89, 282-290 (1995).
175. Imashuku S, Hibi S, Ohara T et al. Effective control of Epstein-Barr virusrelated hemophagocytic lymphohistiocytosis with immunochemotherapy. Blood 93, 1869-1874 (1999).
176. Imashuku S, Hibi S, Kuriyama K et al. Management of severe neutropenia with cyclosporin during initial treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis. Leuk. Lymphoma 36(3-4), 339-346 (2000).
177. Perel Y, Alos N, Ansoborlo A, Carrere A, Guillard J-M. Dramatic efficacy of antithymocyte globulins in childhood EBV-associated haemophagocytic syndrome. Acta Paediatr. 86, 911 (1997).
178. Balamuth NJ, Nichols KE, Paessler M, Teachey DT. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J. Pediatr. Hematol. Oncol. 29, 569-573 (2007).
179. Ravelli A, De Benedetti F, Viola S, Martini A. Macrophage activating syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J. Pediatr. 128, 275-278 (1996).
180. Tristano AG, Casanova-Escalona L, Torres A, Rodriguez MA. Macrophage activation syndrome in a patient with systemic onset rheumatoid arthritis: Rescue with intravenous immunoglobulin therapy. J. Clin. Rheumatol. 9(4), 253-258 (2003).
181. Makay B, Yilmaz S, Turkyilmaz Z et al. Etanercept for therapy-resistant macrophage activation syndrome. Pediatr. Blood Cancer 50, 419-421 (2008).
182. Prahalad S, Bove KE, Dickens D, Lovell DJ, Grom AA. Etanercept in the treatment of macrophage activation syndrome. J. Rheumatol. 28(9), 2120-2124 (2001).
183. Sawar H, Espinoza RL, Gedalia A. Macrophage activation syndrome and etanercept in children with systemic juvenile rheumatoid arthritis. J. Rheumatol. 31, 623 (2004).
184. Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat. Clin. Pract. Rheumatol. 4, 615-620 (2008).
185. Sung L, Weitzman S, Petric M, King SM. The role of infections in primary hemophagocytic lymphohistiocytosis: A case series and review of the literature. Clin. Infect. Dis. 33(10), 1644-1648 (2001).
186. Imashuku S, Teramura T, Morimoto A, Hibi S. Recent developments in the management of haemophagocytic lymphohistiocytosis. Expert Opin. Pharmacother. 2, 1437-1448 (2001).
187. Henzan T, Nagafuji K, Tsukamoto H et al. Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am. J. Hematol. 81, 59-61 (2006).
188. Olin RL, Nichols KE, Naghashpour M et al. Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. Am. J. Hematol. 83, 747-749 (2008).